Multiple Myeloma
Multiple Myeloma
Advertisement
Patrick DalyMultiple Myeloma | December 4, 2023
Non-Hispanic Black and White patients with MM had comparable links between risk factors and survival in the real world.
Read More
Patrick DalyMultiple Myeloma | December 4, 2023
Heart failure with preserved ejection fraction (HFpEF) had worse mortality and acute kidney injury versus HF with reduced EF.
Patrick DalyMultiple Myeloma | December 4, 2023
HSCT in the first line of therapy achieved consistent survival benefits across subgroups of patients with multiple myeloma.
Patrick DalyMultiple Myeloma | December 4, 2023
In hospitalizations for multiple myeloma, mortality and disability rates were disparately impacted by socioeconomic status.
Cailin ConnerMultiple Myeloma | November 30, 2023
Hispanic patients with multiple myeloma had lower overall response rates to idecabtagene vicleucel.
Patrick DalyMultiple Myeloma | February 1, 2024
Obesity was associated with a higher response rate and faster best response in patients with multiple myeloma.
Patrick DalyMultiple Myeloma | November 9, 2023
Black patients with multiple myeloma achieved similar or superior survival rates compared with White patients in studies.
Patrick DalyMultiple Myeloma | November 9, 2023
Older age, male sex, and racial minority status were associated with mortality within 2 years of multiple myeloma diagnosis.
Patrick DalyMultiple Myeloma | November 9, 2023
Ide-cel exhibited some safety and response differences across patients with multiple myeloma in different racial groups.
Dr. Chadi NabhanHealthcare Unfiltered | November 7, 2023
Specialists from Memorial Sloan Kettering Cancer Center illustrate the association between diet and cancer.
Patrick DalyMultiple Myeloma | October 17, 2023
Modifying or ceasing MM treatment based on negative MRD status may be a promising approach for newly diagnosed patients.
Patrick DalyMultiple Myeloma | October 17, 2023
White patients with MM and diabetes showed worse survival outcomes, but this association was not found in Black patients.
Patrick DalyMultiple Myeloma | October 17, 2023
Phase 1 data showed promising outcomes with elranatamab in MM, and authors recommend a phase 2 dose of 76 mg weekly.
Patrick DalyMultiple Myeloma | October 17, 2023
Patients with MM and renal impairment on DVd showed safety and efficacy comparable with patients without renal impairment.
Patrick DalyMultiple Myeloma | October 17, 2023
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
Patrick DalyMultiple Myeloma | October 17, 2023
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Patrick DalyMultiple Myeloma | October 17, 2023
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
Patrick DalyMultiple Myeloma | October 17, 2023
IMWG multiple myeloma treatment guidelines informed by studies with a major lack of Black patients, study finds.
Patrick DalyMultiple Myeloma | October 17, 2023
Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival.
Cailin ConnerBlood Cancers | October 17, 2023
Age, marital status, and tumor site were independent prognostic factors for extramedullary multiple myeloma.
Advertisement
Advertisement
Latest News

April 16, 2024

Advertisement